Lexicon Pharmaceuticals Inc
LXRX
Company Profile
Business description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Contact
2445 Technology Forest Boulevard
11th Floor
The WoodlandsTX77381
USAT: +1 281 863-3000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
103
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,138.25 | 69.63 | 0.86% |
| DAX 40 | 24,229.08 | 42.59 | 0.18% |
| Dow JONES (US) | 48,487.10 | 29.05 | 0.06% |
| FTSE 100 | 9,753.30 | 104.27 | 1.08% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,177.55 | 17.62 | -0.08% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,834.26 | 6.85 | 0.10% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |